SEC Form 4 · accession 0001012975-16-001318
PDS Biotechnology Corp · PDSB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jun 21, 2016
Accepted (ET)
Jun 23, 2016 · 9:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001472091
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to purchase)F2,F1 | $9.34 | Jun 21, 2016 | A | 30,000 | A | Jun 21, 2017 | Jun 21, 2026 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1One third of the option shares vest upon each of the first, second, and third anniversaries of the Transaction Date.
- F2The option to purchase Common Stock is held directly by Liam Ratcliffe ("Ratcliffe"). Ratcliffe has contractually agreed with New Leaf Venture Partners, L.L.C. (the "Management Company") to exercise the option and sell the shares to be received upon exercise of the option only at the direction of the Management Company. Philippe Chambon, Jeani Delagardelle, Ronald M. Hunt, Vijay Lathi, Liam Ratcliffe and Craig Slutzkin, the officers of the Management Company, disclaim beneficial ownership of such option and shares to be received upon exercise of such option except to the extent of their pecuniary interest therein.